# Alan, the French Unicorn Proving Europe Can Still Dream Big

> Introduction: 480 million euros that change the game

- Author: Maxime Marquette
- Publisher: MadMax (https://mad-max.co)
- Section: Column
- Published: 2026-07-04
- Canonical URL: https://mad-max.co/en/article/alan-cette-licorne-francaise-qui-prouve-que-leurope-peut-encore-rever-grand

## Introduction: 480 million euros that change the game

### A funding round that confirms a bold bet

French health insurance startup **Alan** officially closed, on **June 25, 2026**, a Series G funding round of **480 million euros**, led primarily by Dutch investor **Prosus**, propelling the company to a valuation of **5.5 billion euros**.

This deal comes just three months after a previous round of **100 million euros** completed in March 2026 at an already impressive valuation of **5 billion euros**, confirming the sustained appetite of **international investors** for this French company that has become one of the most accomplished showcases of **European health tech**.

### More than a billion euros raised since founding

With this new funding round, **Alan** has now raised more than **1.2 billion euros** since its creation, a colossal amount for a company that nonetheless operates in only four countries: **France**, **Belgium**, **Spain** and **Canada**.

This level of funding places **Alan** among the most highly capitalized **French tech unicorns** in its recent history, a powerful symbol for a French ecosystem that sometimes struggles to retain its best companies against the historic pull of American Silicon Valley.

*I must admit a certain legitimate pride at this kind of news: for decades, we were told over and over that Europe couldn't create global tech champions, and Alan demonstrates a little more each year that this supposed fatality was never really true.*

## Who is Prosus, the discreet giant behind the deal

### A Dutch investor with worldwide reach

**Prosus**, an investment group based in the Netherlands, is directly investing **400 million euros** in this deal, a considerable sum illustrating the confidence placed in **Alan's** business model by one of the world's largest technology investors.

**Prosus** is notably known as the main shareholder of Chinese giant **Tencent** and owner of delivery platform **Just Eat Takeaway**, which gives this new investment in **Alan** a strategic reach that extends well beyond the French or European context alone.

### Other prestigious investors join the deal

Alongside **Prosus**, the Canadian fund **Teachers' Venture Growth**, the **investment arm of the pension plan** for teachers in **Ontario**, is also taking part in this funding round, as is longtime **European fund** **Index Ventures**, already a long-standing investor in the French company.

British **family fund** **Dara Holdings** is also entering the cap table, marking the arrival of a new type of institutional investor within **Alan's** already diversified **shareholder structure**.

*Seeing a Dutch fund tied to Tencent invest heavily in a French health unicorn strikes me as a perfect symbol of our economic era: traditional boundaries between Western and Asian capital are fading, and Europe must learn to navigate this reality intelligently rather than fear it.*

## A business model that has proven itself

### Growth numbers that impress

**Alan** now claims more than **1.1 million insured members** across its four active markets, generating an annual recurring revenue exceeding **800 million euros**, with impressive growth of **53%** compared to the previous year.

Another particularly reassuring signal for investors: the company has reached **profitability** in its historic French market, a **pivotal milestone** rarely reached this quickly by tech startups operating in a **sector as regulated** as health insurance.

### An approach focused on prevention rather than coverage alone

Unlike **traditional insurers** focused almost exclusively on reimbursing care already provided, **Alan** bets on an **active prevention** approach, combining digital technology, personalized support and **early detection** of health issues to reduce overall costs while improving the well-being of its members.

This philosophy of **prevention rather than cure** lies at the heart of the company's **value proposition**, a **strategic positioning** that largely explains investors' sustained enthusiasm for this differentiated business model.

*This preventive approach strikes me as exactly the direction all Western health systems, public and private alike, should be heading: better to invest in early detection than to keep indefinitely financing the costly consequences of our collective negligence.*

## The founders behind this entrepreneurial success

### A vision born from frustration with a system seen as archaic

The company was founded by **Jean-Charles Samuelian-Werve** and **Charles Gorintin**, two French entrepreneurs convinced that the **traditional health insurance system**, seen as slow, opaque and poorly focused on user experience, could be entirely reinvented through modern digital technology.

Their initial bet, which could have seemed risky in a sector as regulated and dominated by powerful **established players**, has paid off over the years, turning **Alan** into an essential **reference point** in European health tech.

### Renowned investors, including from the world of sports

Interestingly, and unusually for the health tech world, the company counts among its longtime investors French footballers **Kylian Mbappé** and **Antoine Griezmann**, two globally known sports figures who chose to bet part of their personal fortune on this French entrepreneurial venture.

This presence of **sports personalities** in a tech company's cap table illustrates a growing trend among top-level athletes to diversify their investments toward promising sectors like digital health, rather than the **traditional investments** usually favored.

*I find it amusing, but also telling, that world-famous footballers would choose to invest in health insurance rather than in flashier assets: it may be a sign that even the biggest sports fortunes are starting to take digital health issues seriously.*

## A European context favorable to health tech

### A sector in full ferment across the continent

The **European health tech** sector has seen a particularly sustained investment momentum for several years, driven by **population aging**, growing pressure on **public health systems** and the increasing appetite of European consumers for digital solutions to manage their own health.

This underlying trend directly benefits companies like **Alan**, which position themselves at the intersection of two traditionally conservative sectors, insurance and healthcare, while injecting a **culture of technological innovation** typical of the world's best startups.

### France, fertile ground despite regulatory obstacles

Despite a **regulatory environment** often seen as restrictive for young tech companies, **France** has, in recent years, managed to produce several tech unicorns of international scale, with **Alan** today standing as one of the most accomplished examples in the specific sector of digital health.

This French success fits within a broader **political will** to strengthen **European technological sovereignty**, an issue deemed crucial in the face of the **persistent dominance** of **American tech giants** and the **rapid rise** of **Chinese technological ambitions**.

*Every success like Alan's strikes me as another brick in the still-fragile edifice of European technological sovereignty: we don't need to copy the American model, but to build our own path, rooted in our values and our specific needs.*

## International expansion ambitions

### Four new markets targeted within eighteen months

The funds raised in this Series G round will primarily finance an ambitious international expansion, with the stated goal of launching **Alan's** operations in **four new countries** over the next **eighteen months**, a particularly sustained **growth pace** for a company in this heavily regulated sector.

This rapid geographic expansion represents both a major growth opportunity and a **considerable operational challenge**, with each new national market requiring **specific regulatory adaptation** in the sensitive field of health insurance.

### A massive investment in artificial intelligence

A significant portion of this new capital will also be devoted to developing advanced capabilities in **artificial intelligence**, a **strategic focus** deemed essential by **Alan's** leadership for improving the personalization of **care pathways** and the platform's **overall operational efficiency**.

This technological investment is part of a **global race** in which digital health companies are all seeking to integrate artificial intelligence to improve early diagnosis, personalized prevention and the overall efficiency of their services for members.

*Integrating artificial intelligence into digital health is no longer an option but a competitive necessity: Western companies that fail to invest heavily in this direction risk falling behind competitors, particularly Asian ones, less concerned with the ethical questions surrounding health data.*

## The persistent challenges of an ultra-regulated sector

### The complexity of **national regulatory frameworks**

**Alan's** international expansion inevitably runs into the complexity of regulatory frameworks specific to each European national market, with the health insurance sector remaining one of the most strictly regulated across the continent, with requirements often very different from one country to another.

This **European regulatory fragmentation** has historically been a major brake on the rapid growth of tech companies in the health sector, a structural obstacle that even a company as well capitalized as **Alan** will have to carefully navigate country by country.

### The sensitive issue of health data protection

Managing particularly sensitive health data also imposes strict obligations on **Alan** regarding **cybersecurity** and **privacy protection**, in accordance with the European **General Data Protection Regulation**, one of the most demanding legal frameworks in the world on this matter.

This European regulatory rigor, while sometimes seen as a brake on rapid innovation, also serves as a differentiating argument against international competitors less scrupulous on these crucial issues of personal medical data confidentiality.

*I believe this European regulatory rigor on health data, often criticized as a brake on innovation, could instead become a long-term competitive advantage: consumer trust is worth a great deal, and Europe has the opportunity to build it better than anyone else.*

## Comparison with American and Asian models

### An approach different from that of American giants

Unlike major American health insurers, often criticized for the complexity of their **pricing structures** and their perceived lack of transparency toward consumers, **Alan** bets on a **simplified user experience** and direct communication with its members through intuitive digital tools.

This difference in cultural and commercial approach partly explains why **Alan's** model resonates particularly well with young companies and European workers seeking a health insurance experience that is less bureaucratic than what traditional market players have historically offered.

### China, a technological growth model to watch

On a global scale, **Chinese digital health companies** benefit from access to considerable volumes of data and often more direct **state support**, which accelerates their technological development but also raises legitimate questions about the privacy protection of users involved with these platforms.

Faced with this potentially formidable Chinese competition in the medium term, Europe must continue to bet on its own tech champions like **Alan**, capable of combining rapid innovation with rigorous respect for **Western ethical standards** regarding personal data.

*I remain convinced that the West must never sacrifice its ethical standards on the altar of technological speed to compete with China: our long-term competitive advantage lies precisely in the trust we can inspire, unlike more opaque models.*

## The impact on the French startup ecosystem

### A ripple effect for young French companies

**Alan's** continued success sends a strong positive signal to the entire **French entrepreneurial ecosystem**, demonstrating that it is possible to build, from **Paris**, a genuinely internationally scaled tech company without necessarily having to move its headquarters to the United States to attract world-class capital.

This ripple effect could encourage more **young French talent** to venture into tech entrepreneurship, reassured by the tangible proof that success on **Alan's** scale remains achievable from French soil without requiring a systematic entrepreneurial exile.

### A mentoring role for the next generation of entrepreneurs

**Alan's** founders today play, whether they explicitly claim it or not, a role as **informal mentors** for a new generation of French entrepreneurs aiming to build tech companies of comparable scale in other traditionally conservative sectors of the French economy.

This dynamic of informal mentorship, often underestimated in traditional economic analyses, significantly contributes to the **gradual maturation** of the entire French tech entrepreneurial ecosystem over the years.

*I believe the real impact of a company like Alan goes far beyond its own financial results: an entire French ecosystem gains collective confidence with every new success of this magnitude, a psychological effect just as important as the numbers themselves.*

## Risks and uncertainties to watch closely

### The **constant pressure of profitability** at scale

Despite already achieving profitability in its historic French market, **Alan** will need to demonstrate its ability to sustain this financial performance while simultaneously financing an ambitious international expansion into four new markets, an always delicate financial balancing act for fast-growing tech companies.

Recent global tech history is full of examples of companies that raised considerable sums before running into major difficulties during **overly rapid international expansion phases**, a precedent that calls for analytical caution even in the face of very encouraging current results.

### A valuation that will need to keep justifying itself

A valuation of **5.5 billion euros** also places continuous performance pressure on **Alan** from its investors, who will naturally expect a sustained growth trajectory that eventually justifies a possible **stock market listing** or some other form of **profitable financial exit** for all shareholders involved.

This constant financial pressure, while manageable for such a well-capitalized company, nonetheless constitutes a risk factor to watch closely in the coming years of development for this French unicorn that has become a continental benchmark.

*I remain cautious in the face of the **media euphoria** surrounding this funding round: an impressive valuation is never a guarantee of long-term success, and tech history is full of examples of unicorns that failed to turn their initial promise into lasting success.*

## What this raise says about current **European attractiveness**

### A positive signal for international investors

This **480-million-euro** deal confirms that Europe, and France in particular, remains a credible investment destination for international tech capital, despite recurring concerns about the **continent's economic competitiveness** compared to the United States and Asia.

This positive signal could encourage other international investors, hesitant until now, to more seriously consider investment opportunities within the European tech ecosystem, particularly in high-societal-impact sectors like digital health.

### A reminder that the West still holds a lead

Faced with increasingly intense global tech competition, particularly from China, this kind of European success is a reminder that the West still retains considerable assets: **highly skilled human capital**, a **reliable regulatory framework** and access to international capital still willing to bet on quality European innovation.

**Alan's** success should serve as a model and inspiration for the entire Western tech ecosystem, demonstrating that it remains possible to build global champions without necessarily sacrificing the ethical and regulatory values that fundamentally distinguish our economic model from that of our main geopolitical rivals.

*I see in this European success much more than just good economic news: it's a concrete argument in the broader debate about the West's ability to remain technologically competitive without giving up its core values of transparency and citizen protection.*

## Next steps expected for Alan

### An **expansion timeline** to watch closely

The coming months will be decisive in observing **Alan's** actual ability to carry out its expansion ambitions into four new markets, a process that will require complex regulatory negotiations and considerable operational investment in each new targeted territory.

Sector observers will also closely monitor the evolution of the company's **key financial indicators**, particularly the maintenance of its French profitability during this costly international expansion phase, demanding in both human and financial resources.

### A possible stock market listing in the medium term

Although no official announcement has been made to that effect, **Alan's** growth trajectory and current capitalization level are already fueling speculation about a possible medium-term stock market listing, a natural step for many tech unicorns that have reached a comparable level of maturity.

Such a move, if it materializes in the coming years, would constitute a new symbolic milestone for the French and European tech ecosystem, further strengthening the continent's credibility as fertile ground for globally scaled tech companies.

*I await the next chapter of this entrepreneurial adventure with cautious optimism: a successful stock market listing for Alan would send an extremely powerful message to an entire generation of European entrepreneurs who still doubt the possibility of succeeding without leaving the continent.*

## A broader symbol for European technological sovereignty

### An issue that goes beyond individual entrepreneurial success alone

Beyond **Alan's** individual success, this funding round fits into a broader geopolitical issue: Europe's ability to develop its own tech champions in strategic sectors like health, rather than relying exclusively on solutions developed by American or Chinese companies.

This European technological sovereignty, long neglected, is gradually becoming an acknowledged political priority at the continental scale, in the face of growing geopolitical tensions that make excessive dependence on foreign technologies increasingly risky in sectors as sensitive as public health.

### A model to replicate in other strategic sectors

**Alan's** success could inspire similar initiatives in other **strategic European sectors**, from defense to energy to **general artificial intelligence**, where Europe is actively seeking to reduce its technological dependence on foreign powers sometimes less aligned with its **fundamental democratic values**.

This broader dynamic of **European technological reappropriation** could, if it continues at this pace, durably transform the **global economic balance of power** in the decades to come, to the benefit of a West able to reclaim part of its **lost strategic autonomy**.

*I believe every European tech success like Alan's is another stone in building genuine Western sovereignty against Chinese ambitions and historic dependence on American technologies: it's a slow fight, but an essential one for our collective future.*

## The role of **independent workers** in Alan's customer base

### A market neglected by traditional insurers

A significant share of **Alan's** customer base comes from independent workers and **small businesses**, a market segment historically poorly served by large traditional French insurers, more oriented toward big companies and their standardized group contracts.

This **niche strategy**, developed from the company's earliest years, allowed **Alan** to build a loyal customer base among French independent workers, often seeking health coverage that is more flexible and better suited to their particular professional status.

### A gradual expansion toward large companies

Building on this initial success with independent workers, **Alan** has gradually extended its offering to larger companies, winning over **human resources departments** seeking a more modern group health insurance experience, one better perceived by their employees than traditional historic solutions.

This **gradual diversification** of the customer base is a key factor in the company's sustained **53%** growth, demonstrating the business model's ability to adapt to different market segments without losing its original value proposition centered on simplicity and prevention.

*I find this initial strategic choice to target independent workers overlooked by major insurers particularly smart: it is often by first serving neglected markets that the most durable companies build their strongest foundations.*

## Conclusion: a success that should inspire, without overshadowing the challenges

### An important milestone, but not a definitive victory

This **480-million-euro** raise undeniably marks an important milestone in the history of **Alan** and the broader French tech ecosystem, but it in no way guarantees the company's future success against the considerable challenges of rapid international expansion and ever-more-intense global competition.

The true measure of **Alan's** success will play out in the years to come, through its concrete ability to maintain profitability while conquering new markets, without ever sacrificing the quality of service and trust that have built its reputation among current members.

### A legitimate reason for optimism for European tech

For now, this success deserves to be celebrated as an encouraging signal that Europe, and particularly **France**, retains the capacity to produce global tech champions capable of competing with the best American and Asian companies, without giving up the values that fundamentally distinguish our Western economic and societal model.

As the global tech race intensifies every year, successes like **Alan's** remind us that the West, and Europe in particular, still holds all the cards needed to remain a major player in global innovation for decades to come.

*Closing this column, what I take away above all is a feeling of measured optimism: Alan alone will not solve all of Europe's technological challenges, but it proves, numbers in hand, that our continent still has everything it needs to keep dreaming big and succeeding on a global scale.*

**By Maxime Marquette, columnist**

## Columnist's transparency note

### Editorial stance

I am not a journalist but a **columnist and analyst**. My expertise lies in observing and analysing the geopolitical, economic and strategic dynamics that shape our world. My work is to take political strategies apart, to understand global economic movements, to put the decisions of international actors in context and to offer analytical perspectives on the changes that are redefining our societies.

I do not claim the cold objectivity of traditional journalism, which stops at reporting facts. **I claim analytical clarity**, rigorous interpretation and a deep understanding of the complex issues that concern us all. My role is to give meaning to the facts, to place them in their historical and strategic context, and to offer a critical reading of events.

### Method and sources

This text keeps the basic distinction between **verified facts and interpretive analysis**. The rule never changes: a factual claim is published only when a verifiable source supports it, and the sources this article actually used are listed under **Sources**, never here.

**Primary source families** used by the publication, when the story has them: official statements from governments and international institutions, public statements by political leaders, reports from intergovernmental organisations, dispatches from recognised international news agencies.

**Secondary source families**: specialised publications, internationally recognised news media, analyses from established research institutions, reports from industry organisations.

When an article cites statistical, economic or geopolitical data, it comes from the institutions that produce it (intergovernmental organisations, central banks, national statistics offices), and the exact institution is named under **Sources**.

### Nature of the analysis

The analyses, interpretations and perspectives in the analytical sections of this article are a **critical, contextual synthesis** based on the information available, the trends observed and the expert comments cited in the sources consulted.

My role is to interpret these facts, to set them in the context of today's geopolitical and economic dynamics, and to give them a coherent meaning within the larger story of the changes shaping our time. These analyses reflect expertise built through continuous observation of international affairs and an understanding of the strategic mechanisms that drive global actors.

This article describes a documented state of affairs on its publication date, not a prediction: later developments may shift its outlook. No update is promised in advance; when an article is corrected or completed, the change is dated in the text.

## Sources

### Primary sources

- [Alan raises 480 million euros to make prevention the new global health standard — Alan, June 25, 2026](https://alan.com/fr-fr/blog/tout-alan/a/alan-leve-480-millions-deuros-pour-faire-de-la-prevention-le-nouveau-standard-mondial-de-la-sante)

- [Alan raises 480 million euros and reaches 5.5 billion euros in valuation — Maddyness, June 25, 2026](https://www.maddyness.com/2026/06/25/alan-leve-480-millions-deuros-et-atteint-55-milliards-deuros-de-valorisation/)

- [Alan raises Series G from Prosus at higher valuation — Sifted, June 2026](https://sifted.eu/articles/alan-prosus-raise-series-g-valuation-health-tech)

### Secondary sources

- [Prosus investment values health insurer Alan — The Wall Street Journal](https://www.wsj.com/finance/investing/prosus-investment-values-health-insurer-alan-at-6-3-billion-4331cb92)

- [Alan, the healthtech backed by Mbappé and Griezmann, closes 480-million round — Cinco Días, June 25, 2026](https://cincodias.elpais.com/companias/2026-06-25/alan-la-healthtech-participada-por-mbappe-y-griezmann-cierra-una-ronda-de-480-millones-con-una-valoracion-de-5500-millones.html)

- French health insurtech Alan raises 480 million Series G — TechCrunch, July 2, 2026

---

Source: Maxime Marquette, MadMax. When citing, name the author and link https://mad-max.co/en/article/alan-cette-licorne-francaise-qui-prouve-que-leurope-peut-encore-rever-grand